N. Flaum

发表

BRCA1/2 in non-mucinous epithelial ovarian cancer: tumour with or without germline testing?

G. Jayson, F. Lalloo, G. Burghel, 2022, British Journal of Cancer.

Everolimus in the treatment of neuroendocrine tumors of the respiratory and gastroenteropancreatic systems.

J. Valle, M. McNamara, W. Mansoor, 2016, Future oncology.

Specialist oncological surgery for removal of the ovaries and fallopian tubes in BRCA1 and BRCA2 pathogenic variant carriers may reduce primary peritoneal cancer risk to very low levels

D. Evans, C. Holland, E. Harkness, 2020, International journal of cancer.

Challenging the believed proportion of ovarian cancer attributable to BRCA2 versus BRCA1 pathogenic variants.

F. Lalloo, E. Crosbie, E. Woodward, 2019, European journal of cancer.

oncological surgery for removal of the ovaries and fallopian tubes in BRCA 1 and BRCA 2 pathogenic variant carriers may reduce primary peritoneal cancer risk to very low levels

C. Holland, E. Harkness, F. Lalloo, 2022 .

Financial burden and financial toxicity in patients with colorectal, gastro-oesophageal, and pancreatobiliary cancers: A UK study

D. Cunningham, G. Papaxoinis, A. Backen, 2020 .

High detection rate from genetic testing in BRCA-negative women with familial epithelial ovarian cancer.

F. Lalloo, E. Crosbie, D. Evans, 2022, Genetics in medicine : official journal of the American College of Medical Genetics.

Predicting the likelihood of a BRCA1/2 pathogenic variant being somatic by testing only tumour DNA in non-mucinous high-grade epithelial ovarian cancer

G. Jayson, F. Lalloo, D. G. Evans, 2022, Journal of Clinical Pathology.

Epithelial ovarian cancer risk: A review of the current genetic landscape

D. G. Evans, E. Crosbie, R. Edmondson, 2019, Clinical genetics.

Is Reflex Germline BRCA1/2 Testing Necessary in Women Diagnosed with Non-Mucinous High-Grade Epithelial Ovarian Cancer Aged 80 Years or Older?

G. Jayson, F. Lalloo, G. Burghel, 2023, Cancers.

Mainstreaming germline BRCA1/2 testing in non-mucinous epithelial ovarian cancer in the North West of England

G. Jayson, D. Evans, E. Harkness, 2020, European Journal of Human Genetics.

Prevalence of germline pathogenic BRCA1/2 variants in sequential epithelial ovarian cancer cases

G. Jayson, D. Evans, G. Burghel, 2019, Journal of Medical Genetics.

Dominant‐negative pathogenic variant BRIP1 c.1045G>C is a high‐risk allele for non‐mucinous epithelial ovarian cancer: A case‐control study

D. Evans, E. Crosbie, R. Edmondson, 2021, Clinical genetics.

Identifying modifiable and non-modifiable risk factors of epithelial ovarian cancer—can we get it better?

D. Evans, N. Flaum, D. Evans, 2019, Gynecology and Pelvic Medicine.

Integrating radiation therapy with emerging systemic therapies: Lessons from a patient with cerebral radionecrosis, spinal cord myelopathy, and radiation pneumonitis.

P. Lorigan, G. Whitfield, R. Hawkins, 2016, Practical radiation oncology.

Adjuvant chemotherapy and outcomes in patients with nodal and resection margin‐negative pancreatic ductal adenocarcinoma: A systematic review and meta‐analysis

J. Valle, R. Hubner, E. Amir, 2019, Journal of surgical oncology.

BRCA1/2 in non-mucinous epithelial ovarian cancer: tumour with or without germline testing?

G. Jayson, F. Lalloo, G. Burghel, 2022, British Journal of Cancer.

Cross-cultural Adaptation of the Proffit Instruments to Measure Financial Toxicity in People Living With Cancer Within a UK Population.

S. Riva, D. Ashcroft, N. Cook, 2023, Journal of cancer policy.

MSH2 is the very young onset ovarian cancer predisposition gene, not BRCA1

F. Lalloo, E. Crosbie, E. Woodward, 2023, Journal of Medical Genetics.

Outcomes of octogenarian (≥ 80 yo) patients with advanced non-small cell lung cancer (NSCLC): A single institution experience at the Christie Hospital.

M. Howell, Y. Summers, P. Taylor, 2016, Lung cancer.